



GOALS OF THE MEETING:

- To present a snapshot of current OI basic and clinical research in centres in Europe
- To inspire closer collaboration between basic and clinical researchers
- To support the younger generation of OI researchers
- To highlight opportunities for data sharing
- To facilitate the development of consortia

MEETING OUTLINE:

All times Central European Time (CET)

14.00	Welcome and Introduction <i>Oliver Semler (Germany)</i>
--------------	---




CLINICAL RESEARCH

Moderators: *Claire Hill (UK)/Inger-Margrethe Paulsen (Norway)*

14.10	Setting the scene: Where are we now with clinical research? <i>Nick Bishop (UK)</i>
14.25	Losartan/Remedi4all <i>Nick Bishop (UK)</i>
14.30	IMPACT survey <i>Frank Rauch (Canada)</i>
14.40	Eurr BONE <i>Natasha Appelman-Dijkstra (The Netherlands)</i>
14.50	Danish epidemiological research <i>Lars Folkestad (Denmark)</i>
15.00	RUDY <i>Kassim Javaid (UK)</i>
15.05	Remodelling an existing rare disease registry to be used in a regulatory context <i>Luca Sangiorgi (Italy)</i>
15.15	TOPAZ <i>Stuart Ralston (UK)</i>
15.20	BOOSTB4 <i>Cecilia Götherström (Sweden)</i>



**15.30
BREAK**



BASIC SCIENCE

Moderators: Oliver Semler (Germany)/Lida Zhytnik (Estonia/The Netherlands)

15.45	Setting the scene: Where are we now with basic science? <i>Antonella Forlino (Italy)</i>
16.00	A translational approach towards personalized medicine for osteogenesis imperfecta <i>Cecilia Giunta (Switzerland)</i>
16.10	Therapeutic challenges in OI <i>Dimitra Micha (The Netherlands)</i>
16.20	Precision medicine in OI <i>Ivan Duràn (Spain)</i>
16.30	Atypical OI <i>Meena Balasubramanian (UK)</i>




16.40
BREAK

16.55	The Cologne pipeline for analyzing extracellular matrix in OI <i>Frank Zauke (Germany)</i>
17.05	Rare forms of OI <i>Valérie Cormier-Daire (France)</i>
17.15	From genomics to zebrafish and back <i>Paul Coucke (Belgium)</i>
17.25	Micro RNA expression in OI <i>Alexandre Mercier (France)</i>
17.35	Bone quality in physiological and pathological conditions <i>Björn Busse (Germany)</i>



17.45
BREAK



FROM COLLABORATION TO CONSORTIA

Moderators: Ingunn Westerheim (Norway)

18.00	<p>How to manage bench to bedside: experiences and insights from the BBDC <i>Brendan Lee (USA)</i></p>
18.15	<p>Concurrent breakout sessions Includes discussion on how to facilitate collaborative research</p>
	<p>Bench to bedside: development of new treatments Group lead: Lida Zhytnik (Estonia/Netherlands)</p>
	<p>Bench to bedside: understanding the molecular basis of rare diseases Group lead: Paul Coucke (Belgium)</p>
	<p>Registries and outcomes Group lead: Lars Folkestad (Denmark)</p>
	<p>Phenotypic variability in OI Group lead: Antonella Forlino (Italy)</p>
	<p>Unmet needs in OI research Group lead: Ingunn Westerheim (Norway)</p>
	<p>How to involve patients in your project Group lead: Stephanie Claeys (Belgium)</p>
18.45	<p>Group feedback, summing up and next steps <i>Moderators: Lars Folkestad (Denmark)/Ingunn Westerheim (Norway)</i></p>

**THE
END** 19.00
CLOSE